In Vivo and In Vitro Interactions of Chlorpromazine and Melanin

  • Arthur G. Bolt
  • Irene S. Forrest


A pronounced affinity between melanin and chlorpromazine has been known since the early 1960’s, when Potts [1] in this country and Rutschmann and associates [2] of the Sandoz Laboratories at Basel detected accumulation of phenothiazine derivatives in the melanin-bearing eye tissues of experimental animals. The drug concentration was found to exceed the uniform rate of distribution by a factor of 30 to 50, depending on the phenothiazine compound used. We previously reported on chlorpromazine levels in the autopsied tissues of a chronically dosed patient [3] and found the drug content in hair higher than in any of the visceral, bone, or keratinous tissues examined. In 1964, Greiner and his group [4–6] called attention to late side effects of high and prolonged doses of chlorpromazine, manifested by “melanosis” in a genetically predisposed group of patients.


Drug Content Glucuronic Acid Dose Patient Drug Metabolite Phenothiazine Derivative 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Potts, A.M.: Uveal pigment and phenothiazine compounds, Tr. Am. Ophth. Soc. 60:517, 1962.PubMedGoogle Scholar
  2. 2.
    Rutschmann, J., et al.: Localization of phenothiazine s in the eye, Psychopharmacology Service Center Bulletin 2(5):73, 1962.PubMedGoogle Scholar
  3. 3.
    Forrest, F.M., et al.: Clinical, biochemical, and post-mortem studies on a patient treated with chlorpromazine, Agressologie 4:259, 1963.PubMedGoogle Scholar
  4. 4.
    Greiner, A.C., and Berry, K.: Skin pigmentation and corneal and lens opacities with prolonged chlorpromazine therapy, Can. Med. Assoc. J. 90:363, 1964.Google Scholar
  5. 5.
    Greiner, A.C., and Nicolson, G. A.: Pigment deposition in viscera associated with prolonged chlorpromazine therapy. Can. Med. Assoc. J. 91:627, 1964.PubMedGoogle Scholar
  6. 6.
    Greiner, A.C., et al.: Therapy of chlorpromazine melanosis. Can. Med. Assoc. J. 91:636, 1964.PubMedGoogle Scholar
  7. 7.
    Piattelli, M., and Nicolaus, R. A.: The Structure of melanins and melanogenesis: I, Tetrahedron 15:66, 1961CrossRefGoogle Scholar
  8. 7a.
    Nicolaus, R. A.: Biogenesis of melanins, Rass. Med. Sper. 9 (Suppl. 1): 1, 1962.Google Scholar
  9. 8.
    Bolt, A.G.: Interactions between human melanoprotein and chlorpromazine derivatives. I. Isolation and purification of human melanoprotein from hair and melanoma tissue, Life Sci. 6:1277, 1967.PubMedCrossRefGoogle Scholar
  10. 9.
    Forrest, I.S., et al.: In vitro interaction of chlorpromazine and melanin, Agressologie 7:147, 1966.PubMedGoogle Scholar
  11. 10.
    Bolt, A.G., and Forrest, I.S.: Interactions between human melanoprotein and chlorpromazine derivatives. II. Spectrophotometric studies, Life Sci. 6:1285, 1967.PubMedCrossRefGoogle Scholar
  12. 11.
    Greiner, A.C., and Nicolson, G.A.: Schizophrenia-melanosis—cause or side effect?, Lancet (7423):1165, 1965.CrossRefGoogle Scholar
  13. 12.
    Bolt, A.G., and Forrest, I.S.: 7-Hydroxychlorpromazine in normal and abnormal human chlorpromazine metabolism, Proc. Western Pharmacol. Soc. 10:11, 1967.Google Scholar
  14. 13.
    Zelickson, A.S.: Skin changes and chlorpromazine, J. Am. Med. Assoc. 198:341, 1966.CrossRefGoogle Scholar
  15. 14.
    Perry, T.L., et al.: 7-Hydroxychlorpromazine: Potential toxic drug metabolite in psychiatric patients, Science 146:81, 1964.PubMedCrossRefGoogle Scholar
  16. 15.
    Forrest, I.S., et al.: Studies on chlorpromazine metabolites in mammalian tissues, Abstract No. 546, Fed. Proc. 26(2):353, 1967.Google Scholar
  17. 16.
    Fishman, V., and Goldenberg, H.: Metabolism of chlorpromazine IV. Identification of 7-hydroxychlorpromazine and its sulfoxide and desmethyl derivatives, Proc. Soc. Exptl. Biol. Med. 112:501, 1963.Google Scholar
  18. 17.
    Beckett, A.H., et al.: Metabolism of chlorpromazine in humans, Biochem. Pharmacol. 12:779, 1963.PubMedCrossRefGoogle Scholar
  19. 18.
    Bolt, A.G., et al.: Quantitative studies of urinary excretion of chlorpromazine metabolites in chronically dosed psychiatric patients, J. Pharm. Sci. 55:1205, 1966PubMedCrossRefGoogle Scholar
  20. 18a.
    Bolt, A. G., and Forrest, I.S.: Assay of chlorpromazine glucuronides in human urine, J. Pharm. Sci. 56:1533, 1967.PubMedCrossRefGoogle Scholar
  21. 19.
    Forrest, F.M., et al.: Incidence of late “melanosis” side effects in chronic mental patients after long term phenothiazine therapy, Proc. Western Pharmacol. Soc. 9:18, 1966.Google Scholar
  22. 20.
    Gunby, B. et al.: Late oculocutaneous complications in phenothiazine therapy, Acta Pyschiat. Scand. 41:97, 1965.Google Scholar
  23. 21.
    Gombos, G.M., and Yarden, P.E.: Ocular and cutaneous side effects after prolonged chlorpromazine treatment, Am. J. Psychiat. 123:872, 1967.PubMedGoogle Scholar
  24. 22.
    Forrest, I.S., and Bolt, A.G.: Inter-species differences in chlorpromazine metabolism, Proc. Western Pharmacol. Soc. 10:30, 1967.Google Scholar

Copyright information

© Springer Science+Business Media New York 1968

Authors and Affiliations

  • Arthur G. Bolt
  • Irene S. Forrest

There are no affiliations available

Personalised recommendations